Abstract
The SARS-CoV-2 Omicron BA.1 variant is rapidly spreading worldwide, possibly outcompeting the Delta strain. We investigated the empirical serial interval for both variants using contact tracing data. Overall, we observed a shorter serial interval for Omicron compared to Delta, suggesting faster transmission. Furthermore, results indicate a relation between the empirical serial interval and the vaccination status for both the Omicron and the Delta variant. Consequently, with the progression of the vaccination campaign, the reasons for and extent of dominance of Omicron over Delta may need further assessment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N.H. and A.T. acknowledge funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (Grant agreement number 101003688). N.H. acknowledges funding from the Antwerp Study Centre for Infectious Diseases (ASCID) and the chair in evidence-based vaccinology at the Methusalem Centre of Excellence consortium VAX-IDEA. This project was supported by the VERDI project (101045989), funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data analyses carried out in this work are among the legal tasks of Sciensano (artikel 4.4 Wet tot oprichting van Sciensano; article 4.4 Law establishment Sciensano). Article 4.4 explicitly states that Sciensano is authorized to collect, validate, analyse, report and archive data of a personal nature concerning public health. Sciensano is further authorized to make these processed data available with approval of the qualified sectoral committees. Such approval for these data was obtained from the Information Security Committee Social Security and Health (ISC).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Transmission pair data (without vaccination status for identifiability reasons) and R code for the analysis are available on https://github.com/cecilekremer/serial_interval
